37 research outputs found
Flavonoids and Related Compounds in Non-Alcoholic Fatty Liver Disease Therapy
P. 2991-3012Non-alcoholic fatty liver disease (NAFLD), the hepatic manifestation of metabolic syndrome,
is one of the most common chronic liver diseases, which may progress to fibrosis, cirrhosis and
hepatocellular carcinoma. NAFLD is characterized by the accumulation of lipids in the liver arising from
multiple factors: increased fatty acid uptake, increased de novo lipogenesis, reduced fatty acid oxidation
and very low density lipoproteins (VLDL) secretion. Most therapeutic approaches for this disease are
often directed at reducing body mass index and improving insulin resistance through lifestyle
modifications, bariatric surgery and pharmacological treatments. Nevertheless, there is increasing
evidence that the use of natural compounds, as polyphenols, exert multiple benefits on the disorders
associated with NAFLD. These molecules seem to be able to regulate the expression of genes mainly
involved in de novo lipogenesis and fatty acid oxidation, which contributes to their lipid-lowering effect
in the liver. Their antioxidant, anti-inflammatory, antifibrogenic and antilipogenic properties seem to
confer on them a great potential as strategy for preventing NAFLD progression. In this review, we
summarized the effects of these compounds, especially flavonoids, and their mechanisms of action, that
have been reported in several studies carried out in in vitro and in vivo models of NAFL
Dental emergency care in Spain during the state of alarm due to COVID-19 pandemic
The first state of alarm due to COVID-19 in Spain led to limit dental treatment exclusively to emergencies. The objective of the survey was to evaluate the amount and type of emergencies attended during this period, as well as to know how they were solve
Intestinal microbiota transplantation to germ-free mice in a in vivo model of nafld associated with a quercetin treatment
15 p.To select mice donors for intestinal microbiota transplantation
based on its metabolic phenotype in response to a high fat diet (HFD) and quercetin treatment (Q). Intestinal microbiota. Resumen de un trabajo resultado del proyecto de investigación financiado por la Consejería de Educación de la Junta de Castilla y León (referencia LE063U16)S
Intestinal microbiota modulation in obesity-related non-alcoholic fatty liver disease
[EN] Obesity and associated comorbidities, including non-alcoholic fatty liver disease (NAFLD), are a major concern to public well-being worldwide due to their high prevalence among the population, and its tendency on the rise point to as important threats in the future. Therapeutic approaches for obesity-associated disorders have been circumscribed to lifestyle modifications and pharmacological therapies have demonstrated limited efficacy. Over the last few years, different studies have shown a significant role of intestinal microbiota (IM) on obesity establishment and NAFLD development. Therefore, modulation of IM emerges as a promising therapeutic strategy for obesity-associated diseases. Administration of prebiotic and probiotic compounds, fecal microbiota transplantation (FMT) and exercise protocols have shown a modulatory action over the IM. In this review we provide an overview of current approaches targeting IM which have shown their capacity to counteract NAFLD and metabolic syndrome features in human patients and animal models.SIThis work was supported by grants to JG-G and SS-C from Ministerio de Economía y Competitividad/FEDER (BFU2017- 87960-R) and Junta de Castilla y León (LE063U16 and GRS 1888/A/18). DP was supported by a fellowship from Junta de Castilla y León co-financed by the European Social Fund. EN was supported by Fundación de Investigación Sanitaria of León. MG-M was supported by CIBERehd contracts. CIBERehd is funded by the Instituto de Salud Carlos III, Spain
Protective effect of quercetin on high-fat diet-induced non-alcoholic fatty liver disease in mice is mediated by modulating intestinal microbiota imbalance and related gut-liver axis activation
60 p.Gut microbiota is involved in obesity, metabolic syndrome and the progression of
nonalcoholic fatty liver disease (NAFLD). It has been recently suggested that the
flavonoid quercetin may have the ability to modulate the intestinal microbiota
composition, suggesting a prebiotic capacity which highlights a great therapeutic
potential in NAFLD. The present study aims to investigate benefits of experimental
treatment with quercetin on gut microbial balance and related gut-liver axis activation in
a nutritional animal model of NAFLD associated to obesity. C57BL/6J mice were
challenged with high fat diet (HFD) supplemented or not with quercetin for 16 weeks.
HFD induced obesity, metabolic syndrome and the development of hepatic steatosis as
main hepatic histological finding. Increased accumulation of intrahepatic lipids was
associated with altered gene expression related to lipid metabolism, as a result of
deregulation of their major modulators. Quercetin supplementation decreased insulin
resistance and NAFLD activity score, by reducing the intrahepatic lipid accumulation
through its ability to modulate lipid metabolism gene expression, cytochrome P450 2E1
(CYP2E1)-dependent lipoperoxidation and related lipotoxicity. Microbiota composition
was determined via 16S ribosomal RNA Illumina next-generation sequencing.
Metagenomic studies revealed HFD-dependent differences at phylum, class and genus
levels leading to dysbiosis, characterized by an increase in Firmicutes/Bacteroidetes
ratio and in Gram-negative bacteria, and a dramatically increased detection of
Helicobacter genus. Dysbiosis was accompanied by endotoxemia, intestinal barrier
dysfunction and gut-liver axis alteration and subsequent inflammatory gene
overexpression. Dysbiosis-mediated toll-like receptor 4 (TLR-4)-NF-B signaling
pathway activation was associated with inflammasome initiation response and reticulum
stress pathway induction. Quercetin reverted gut microbiota imbalance and related
endotoxemia-mediated TLR-4 pathway induction, with subsequent inhibition of
inflammasome response and reticulum stress pathway activation, leading to the
blockage of lipid metabolism gene expression deregulation. Our results support the
suitability of quercetin as a therapeutic approach for obesity-associated NAFLD via its
anti-inflammatory, antioxidant and prebiotic integrative response.Gut microbiota is involved in obesity, metabolic syndrome and the progression of
nonalcoholic fatty liver disease (NAFLD). It has been recently suggested that the
flavonoid quercetin may have the ability to modulate the intestinal microbiota
composition, suggesting a prebiotic capacity which highlights a great therapeutic
potential in NAFLD. The present study aims to investigate benefits of experimental
treatment with quercetin on gut microbial balance and related gut-liver axis activation in
a nutritional animal model of NAFLD associated to obesity. C57BL/6J mice were
challenged with high fat diet (HFD) supplemented or not with quercetin for 16 weeks.
HFD induced obesity, metabolic syndrome and the development of hepatic steatosis as
main hepatic histological finding. Increased accumulation of intrahepatic lipids was
associated with altered gene expression related to lipid metabolism, as a result of
deregulation of their major modulators. Quercetin supplementation decreased insulin
resistance and NAFLD activity score, by reducing the intrahepatic lipid accumulation
through its ability to modulate lipid metabolism gene expression, cytochrome P450 2E1
(CYP2E1)-dependent lipoperoxidation and related lipotoxicity. Microbiota composition
was determined via 16S ribosomal RNA Illumina next-generation sequencing.
Metagenomic studies revealed HFD-dependent differences at phylum, class and genus
levels leading to dysbiosis, characterized by an increase in Firmicutes/Bacteroidetes
ratio and in Gram-negative bacteria, and a dramatically increased detection of
Helicobacter genus. Dysbiosis was accompanied by endotoxemia, intestinal barrier
dysfunction and gut-liver axis alteration and subsequent inflammatory gene
overexpression. Dysbiosis-mediated toll-like receptor 4 (TLR-4)-NF-B signaling
pathway activation was associated with inflammasome initiation response and reticulum
stress pathway induction. Quercetin reverted gut microbiota imbalance and related
endotoxemia-mediated TLR-4 pathway induction, with subsequent inhibition of
inflammasome response and reticulum stress pathway activation, leading to the
blockage of lipid metabolism gene expression deregulation. Our results support the
suitability of quercetin as a therapeutic approach for obesity-associated NAFLD via its
anti-inflammatory, antioxidant and prebiotic integrative respons
Akkermansia spp. mediates protection from obesity-associated NAFLD development in germ free mice following intestinal microbiota transplantation from high fat diet and quercetin treated donors
1 p.Dysbiosis and gut-liver axis alteration have
been pointed as important contributors to obesity and non-alcoholic
fatty liver disease (NAFLD) development. Modulation of intestinal
microbiota (IM) emerge as a promising therapeutic strategy for
obesity-associated NAFLD. This study aims to determine the effect of
IM transplantation and quercetin supplementation in a high fat diet
(HFD)-based NAFLD model in germ free mice (GFm). Resumen de un trabajo resultado del proyecto de investigación financiado por la Consejería de Educación de la Junta de Castilla y León (referencia LE063U16)S
Intestinal Microbiota Transplantation From HFD-fed and Quercetin Treated Donors Results in a Complex Metabolic Phenotype Transfer that Modulates Obesity-Related NAFLD in Germ Free Mice
2 p.Intestinal microbiota imbalance and related
gut-liver axis activation have been identified as key mechanisms
in nonalcoholic fatty liver disease (NAFLD) development.
Modulation of intestinal microbiota, through
administration of prebiotics or faecal microbiota transplantation,
is a promising therapeutic approach for obesity
associated diseases including NAFLD. The aim of the
present study is to evaluate the benefits of gut microbiota
transplantation from donors to germ free mice (GFm)
following an experimental treatment with the flavonoid
quercetin in a high fat diet (HFD)-based NAFLD model. Resumen de un trabajo resultado del proyecto de investigación financiado por la Consejería de Educación de la Junta de Castilla y León (referencia LE063U16)S
Metabolic Phenotype Transfer Through Gut Microbiota Transplantation from HFD-Fed and Quercetin Treated Donors Modulates Obesity-Related NAFLD in Germ-Free Mice
1 p.Gut microbiota is involved in obesity,
metabolic syndrome and nonalcoholic fatty liver disease
(NAFLD). Strategies to modulate it, including faecal transplantation
and administration of prebiotics as quercetin, are actively
being examined. The present study aims to investigate benefits
of experimental gut microbiota transfer from donors to
germ-free mice (GFm) in a high-fat diet (HFD)-based NAFLD
model. Resumen de un trabajo resultado del proyecto de investigación financiado por la Consejería de Educación de la Junta de Castilla y León (referencia LE063U16)S
Effect of exercise on gut microbiota and metabolic status modulation in an in vivo model of early obesity and NAFLD
1 p.Childhood obesity is one of the most serious
public health concerns from this century, associated with metabolic
syndrome, nonalcoholic fatty liver disease (NAFLD) and gut microbiota
alterations. Physical exercise improves obesity and NAFLD
progression, modulating the gut microbial balance. We aim to
investigate the effect of physical exercise on gut microbiota and the
metabolic status of an in vivo model of early obesity, metabolic
syndrome, and NAFLD. Resumen de un trabajo resultado del proyecto de investigación financiado por la Consejería de Educación de la Junta de Castilla y León (referencia LE063U16)S
Protective effect of quercetin treatment on HFD-induced intestinal dysbiosis and barrier dysfunction in an in vivo model of non-alcoholic fatty liver disease
1 p.Gut microbiota is involved in obesity,
metabolic syndrome and nonalcoholic fatty liver disease (NAFLD).
Quercetin may have the ability to modulate the intestinal microbiota
composition, suggesting therapeutic potential in NAFLD. The present
study aims to investigate the beneficial effect of quercetin treatment
on dysbiosis, intestinal barrier dysfunction and gut-liver axis
alteration in high-fat diet (HFD)-fed mice. Resumen de un trabajo resultado del proyecto de investigación financiado por la Consejería de Educación de la Junta de Castilla y León (referencia LE063U16)S